# CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)

> **NCT02827890** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 20 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Januvia Tab. 100mg
- **DRUG:** Januvia Tab. 100mg + Duvie Tab. 0.5mg

## Key facts

- **NCT ID:** NCT02827890
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2016-04
- **Final completion:** 2016-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02827890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02827890, "CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02827890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*